Nexgel (NXGL) Cash from Financing Activities (2018 - 2025)
Nexgel (NXGL) posted Cash from Financing Activities of -$1.0 million for Q4 2025, down 154.05% on a QoQ basis from $1.9 million in Q3 2025, and down 162.34% year-over-year from $1.7 million in Q4 2024.
Nexgel (NXGL) Cash from Financing Activities (2018 - 2025) Analysis & Trends
Nexgel's Cash from Financing Activities history runs 8 years deep, the most recent figure standing at -$1.0 million for Q4 2025.
- Quarterly Cash from Financing Activities fell 162.34% year-over-year to -$1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $630000.0 (down 83.2% YoY) and the FY2025 annual result came in at $630000.0, down 83.2% from the prior year.
- Cash from Financing Activities was -$1.0 million for Q4 2025 at Nexgel, down from $1.9 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $13.2 million in Q4 2021 and bottomed at -$2.0 million in Q1 2022.
- A 5-year average of $968666.7 and a median of $43500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Peak annual rise in Cash from Financing Activities reached 46550.0% in 2024, while the deepest fall reached 6300.0% in 2024.
- Nexgel's Cash from Financing Activities stood at $13.2 million in 2021, then sank by 101.14% to -$150000.0 in 2022, then soared by 296.0% to $294000.0 in 2023, then surged by 468.03% to $1.7 million in 2024, then sank by 162.34% to -$1.0 million in 2025.
- Business Quant data shows NXGL's Cash from Financing Activities at -$1.0 million in Q4 2025, $1.9 million in Q3 2025, and -$40000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -133.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -414.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -13.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -255.24 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -50.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -48.13 Mn |
| 10 | Nexgel | 3.50 Mn | 2.13 Mn | 819,000.00 | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.04 Mn |
| Dec 31, 2025 | -1.04 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | -40,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Mar 31, 2025 | -215,000.00 |
| Dec 31, 2024 | 1.67 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -64,000.00 |
| Jun 30, 2024 | -64,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Mar 31, 2024 | 929,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Dec 31, 2023 | 294,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Sep 30, 2023 | 88,000.00 |